Out of 300 patients who had taken benoxaprofen for a mean of 6 4 months, 196 These findings show that benoxaprofen is a potent phototoxic drug and that the manufacturers' recommended dosage of 600 mg daily is associated with an unacceptable incidence of side effects in the elderly.
Introduction
Benoxaprofen is a non-steroidal anti-inflammatory drug and was introduced into clinical practice in May 1980. Its pharmacological profile suggests a different mode of action from other such drugs.' The long plasma half life of 30-35 hours means that it can be given once daily.' Well-controlled clinical studies have shown benoxaprofen to be effective in treating rheumatoid arthritis,3 osteoarthritis,4 and ankylosing spondylitis.5
Clinicians have a bewildering choice of over 20 non-steroidal anti-inflammatory agents to prescribe. It is not possible to produce a league table of the efficacy and toxicity of these drugs owing to the conflicting results of clinical trials.' Nevertheless, a non-steroidal anti-inflammatory agent that may be given once daily is convenient, especially in the elderly.
Our experience of treating 300 patients with benoxaprofen provided an opportunity to assess the incidence of clinical side effects of this new drug.
Patients and methods
Three-hundred patients who attended rheumatology clinics between May 1980 and May 1981 began benoxaprofen if the clinician thought that they needed a non-steroidal anti-inflammatory drug. Table I shows their age and sex distribution, the diagnoses, and the durations of disease. All were white, and most had rheumatoid arthritis.
The daily dosage of benoxaprofen was 600 mg in 292 patients, 900 mg in five. Benoxaprofen was increased from 600 mg to 900 mg daily in seven patients and decreased from 600 mg to 300 mg daily in three, the changes being based on clinical response. By December 1981 the mean duration of exposure to benoxaprofen was 6 4 months (range 2 days to 19 months). Fifty patients had received benoxaprofen for more than a year and 113 patients for six to 11 months. We therefore had a cumulative total of over 160 patient-years.
In addition to benoxaprofen, 44 patients with rheumatoid arthritis were taking suppressive agents-prednisolone (25 patients), penicillamine (14) , and gold (5). These drugs were continued with occasional dosage modification depending on clinical requirements. Twentythree patients were receiving an additional non-steroidal antiinflammatory agent to benoxaprofen-indomethacin (6 patients), flurbiprofen (8) , naproxen (3), ibuprofen (3), fenclofenac (2), and fenoprofen (1) .
At each visit patients were questioned about new symptoms. Possible side effects were recorded if the clinician thought that they might be drug related. Specific inquiry was made about gastric symptoms, photosensitivity reactions, and nail changes. The reasons for withdrawing benoxaprofen were also recorded. Facial milia (multiple subepidermal cysts; see figure) were observed in 16 patients (5-3%). These lesions were not present before benoxaprofen and were observed after a mean of 10-8 months (range 5-18 months) of treatment. Milia occurred in 11 patients with rheumatoid arthritis (one of whom was taking gold), two with osteoarthritis, two with Paget's disease, and one with polymyalgia rheumatica (who was also taking 10 mg prednisolone daily). The male to female ratio was 7:9. Nine patients who developed milia had had photosensitivity. Histologically a'typical lesion showed "an epidermoid cyst compatible with the clinical diagnosis of milia."
The most florid example of milia occurred in the patient who was also taking prednisolone.
Three women with rheumatoid arthritis' reported. an increase in facial and forearm hair while taking benoxaprofen 600 mg daily. They were taking no other drugs. Examination confirmed a growth of downy hair at these sites, which was not in androgenic distribution.
Gastric symptoms were the most frequently reported 'gastrointestinal side effect (table V) and occurred in 38 patients (12-6%).
The incidence of gastric side effects rose to 4055% (17 cases) in patient's over 70 and was 8100 (21 cases) in patients 'under 70. Among patients over 70 the incidence of gastric side effects was 70% (7 out of 10 cases) in those with osteoarthritis and 30 7% (8 out of 26) in those with rheumatoid arthritis. 
Discussion
The purpose of this study was to assess the type and incidence of side effects and also the withdrawal rate due to benoxaprofen. We did not assess the efficacy of benoxaprofen, which has been established by controlled clinical trials. [3] [4] [5] In this type of long-term study the incidence of side effects may be artificially high owing to coincidental non-drug-related medical conditions. In clinical trials side effects have been reported in 15% of patients with rheumatoid arthritis taking placebo.7
In our series an incidence of side effects in 65.3% of patients due to benoxaprofen and a withdrawal rate of 3466% due to side effects were higher than reported for other non-steroidal anti-inflammatory drugs. The incidence of side effects in a long-term study of flurbiprofen was 52-5%, and the withdrawal rate due to side effects was 18-8%.8 The higher incidence of side effects due to benoxaprofen was due to the unique photosensitivity reaction and also onycholysis.
In elderly patients who require a non-steroidal anti-inflammatory agent benoxaprofen is convenient as it can be taken once daily. Our inhibiting prostaglandin synthetase activity. Our results show that combining benoxaprofen with another such drug resulted in a very high incidence (73 9%) of side effects and a withdrawal rate of 34 8% because of side effects. That photosensitivity occurred during the summer in 83 out of 166 patients taking benoxaprofen indicates that the drug is a potent photosensitiser. The severity of the reaction was such that 26 patients had to stop taking benoxaprofen. This incidence of photosensitivity (50 0%) was much higher than the 9% incidence reported in North America." This may, however, have been partly due to the fact that all of our patients were white, though the proportion of dark-skinned patients in the North American study was not stated. Skin complexion is the determining factor as regards the probability of developing photosensitivity. The lower incidence of photosensitivity in the elderly in our series might have been due to less exposure to the sun.
Benoxaprofen photosensitisation is due to a phototoxic reaction, as the photochemically induced skin response is without an immunological basis. Evidence suggests that the photoreactive molecule is benoxaprofen rather than a metabolite." Photosensitivity occurs within a couple of days' of taking 600 mg doses, and the reaction is transient. The reaction is due to both ultraviolet A and ultraviolet B rays." The role of sunscreens, which should protect against ultraviolet A and ultraviolet B, in preventing benoxaprofen photosensitivity needs to be established in clinical practice.
The observation that oncycholysis occurred in 12 6% of patients treated with benoxaprofen is similar to other reports." The onycholysis was similar to that induced by demeclocycline,'4 which is also phototoxic. Our anecdotal evidence suggests that benoxaprofen onycholysis is in part related to exposure to sunlight. Nevertheless, several cases of onycholysis were observed in toenails that had not been exposed to sunlight. If benoxaprofen onycholysis is due solely to photosensitivity it should be preventable by the application of an opaque nail varnish. Seven patients reported an increased rate of nail growth while taking benoxaprofen, three of whom had onycholysis. The rate of nail growth is increased in idiopathic onycholysis."5 It has yet to be determined whether benoxaprofen can increase the rate of nail growth.
Milia are quite common at all ages and may occur after sunbathing and also in areas of chronic corticosteroid-induced atrophy. '6 We are unaware of published reports of the association of milia with benoxaprofen, which occurred in 16 of our patients (5-30%). Milia were in part related to the duration of exposure to benoxaprofen, as all cases occurred after five months of treatment (mean 10 8 months).
Hypertrichosis, which occurred in three patients, has not been reported in association with benoxaprofen. The hypertrichosis may have been unrelated to benoxaprofen, though we could not identify another cause. The patients were taking no other drugs. Drug-induced hypertrichosis is a frequent complication of treatment with minoxidil" 7 and -has also been reported in association with cortisone and penicillamine. '6 The incidence of gastric side effects associated with benoxaprofen (12 6%) was similar to that in a study of Our results suggest that in the elderly a dose of 600 mg daily is associated with an unacceptable incidence of gastric side effects. It is not clear why elderly patients with osteoarthritis were more prone to gastric side effects than patients with rheumatoid arthritis. Tyson and Glynne reported that in patients over 60 with osteoarthritis benoxaprofen caused more gastric side effects than did ibuprofen, whereas in patients under 60 the reverse was true. 4 Compared with other non-steroidal anti-inflammatory agents benoxaprofen has a unique side-effect profile. It remains to be established whether benoxaprofen has the disease-modifying properties that were claimed at the enthusiastic launch of the drug.' 9 
Introduction
Benoxaprofen (Opren, Dista) is a non-steroidal anti-inflammatory agent derived from propionic acid that has been on general release for over a year, during which time it has produced several unusual dermatological side effects. To alert practitioners of their unusual nature we record here the side effects seen in patients referred to our two departments, which serve a population of about 700 000.
Studies and results

PHOTOSENSITIVITY
Initial trials of benoxaprofen1 reported a 10%, incidence of photosensitivity rashes. Since many patients complained of burning, itching, or redness when in sunlight while taking the drug we investigated this in six consecutive patients with rheumatic disorders who were to receive treatment with benoxaprofen. These studies were carried out using an irradiation monochromator before and at least one week after benoxaprofen 600 mg was taken at night. Each patient lay prone, and a liquid-filled light guide conducted the radiation from the exit slit of the monochromator to the patient's back, an anatomical site
